Bafna Pharmaceuticals Limited has announced its audited financial results for the quarter and year ended March 31, 2026, alongside the outcome of its Board Meeting held on May 29, 2026. The company reported a significant performance improvement in the final quarter of the financial year. Revenue from operations for the quarter stood at INR 42.23 Crores, compared to INR 38.29 Crores in the preceding quarter (December 2025) and INR 39.06 Crores in the corresponding quarter of the previous year (March 2025). The profit for the period was reported at INR 2.75 Crores, reflecting a robust increase from INR 1.84 Crores in the previous quarter and INR 1.31 Crores in the same quarter of the previous year. The detailed comparative analysis of the financial results is presented in the table below:

Bafna Pharmaceuticals Limited is a Chennai-based pharmaceutical company primarily engaged in the manufacturing of pharmaceutical formulations. The company operates from its registered office in Chennai and has a manufacturing facility located in Grantlyon Village. As per the regulatory disclosures, the company is managing legal challenges related to GST demand orders and recoveries of GST refunds, for which it has preferred appeals and obtained stays, maintaining confidence in a positive financial outcome.